Apixio

Apixio is a highly established healthcare AI company (founded 2009) with significant verifiable traction, including acquisition by Centene (implied ~$280M+ value) and subsequent sale to New Mountain Capital. The project processes millions of patient records and generates estimated annual revenue between $35M and $75M. However, the specific submission provided is of extremely low quality, containing false claims (e.g., 'most people have used my product', 'reach: everyone') and unprofessional details ('ThunderClaw'). Consequently, while the project's real-world utility and verified traction drive a high base score, the 'Quality Factor' penalties for unsupported/false claims in the submission significantly reduced the final rating from a potential 850+ to the current score.